SO SÁNH KẾT QUẢ ĐIỀU TRỊ CỦA TENOFOVIR ALAFENAMIDE Ở BỆNH NHÂN VIÊM GAN VIRUS B MẠN TÍNH CÓ HBeAg(+) VÀ HBeAg(-)

Abstract

Tenofovir Alafenamide (TAF) is approved for the treatment of patients with chronic HBV, but the rate of viral response is defferent between HBeAg-positive  and HBeAg-negative patients. A descriptive study on 49 chronic hepatitis B patients treated at Bach Mai Hospital and Hanoi Medical University Hospital to compare the effectiveness of TAF in patients with HBeAg (+)  and thoses with HBeAg (-) as well as the association between viral response and the laboratory change at baseline of  treatment. The primary efficacy endpoint was the proportion of patients with HBV DNA less than 20 IU/mL (HBV-DNA suppression) at week 24 of treatment.

Results: The proportion of HBV-DNA suppression in the HBeAg (-) group is significantly higher than in the HBeAg (+) group; 77.3% versus 37%, p <0.05.There was no different about proportion of ALT normalization between HBeAg(+) and HBeAg(-) group. Patients with HBV-DNA at baseline<6log(copies/ml) have the proportion of viral suppression higher than those with HBV-DNA at baselin >8log(copies/ml), 87.5% versus 31.8%, p<0.05. After 6 months of treatment, there was no association between the proportion of viral suppression and the level of ALT at baselin.

Conclusion: Following up patients after 6 months of treatment, we found that, tenofovir alafenamide hadhigh efficacy for chronic hepatitis Btreatment, especially the viral suppression in HBeAg-negative group was better than in HBeAg-positive group.